Aquestive Therapeutics (AQST) Cash from Operations (2017 - 2026)

Aquestive Therapeutics' Cash from Operations history runs 10 years deep, the most recent figure standing at 14806000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 36.73% year-over-year to 14806000.0 in Q1 2026; TTM through Mar 2026 was 43838000.0, a 10.12% increase from a year earlier, with the FY2025 full-year figure at 52432000.0, down 46.63% from the prior year.
• Cash from Operations retreated to 14806000.0 in Q1 2026 per AQST's latest filing, from 8469000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 8816000.0 in Q1 2023 and bottomed at 23400000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 7907000.0 (2023), against an average of 7011529.41.
• Across the five-year window, Cash from Operations soared 204.4% in 2022 and slumped 406.18% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 8416000.0 in 2022, then tumbled by 158.72% to 4942000.0 in 2023, then plunged by 31.3% to 6489000.0 in 2024, then tumbled by 30.51% to 8469000.0 in 2025, then sank by 74.83% to 14806000.0 in 2026.
• Per Business Quant, the three latest AQST Cash from Operations figures stand at 14806000.0 (Q1 2026), 8469000.0 (Q4 2025), and 12649000.0 (Q3 2025).